603392 万泰生物
2026/03 - 三个月2025/122024/122023/122022/12

盈利能力分析
净资产收益率 ROE (%)-0.363-3.3010.8519.96556.353
总资产报酬率 ROA (%)-0.309-2.7720.6997.81240.693
投入资产回报率 ROIC (%)-0.351-3.1860.8219.62653.875

边际利润分析
销售毛利率 (%)69.85849.32166.19684.15489.536
营业利润率 (%)-11.213-25.7964.17925.43150.031
息税前利润/营业总收入 (%)-10.423-27.0620.41923.59849.361
净利润/营业总收入 (%)-8.577-22.7584.85922.61943.480

收益指标分析
经营活动净收益/利润总额(%)-8.824104.692-222.609117.12997.395
价值变动净收益/利润总额(%)-33.997-23.813216.8678.8670.826
营业外收支净额/利润总额(%)1.9842.425-39.058-0.578-0.239

偿债能力分析
流动比率 (X)4.2124.1764.1623.8583.495
速动比率 (X)3.7323.7863.7333.5193.245
资产负债率 (%)12.88314.31915.25918.01722.580
带息债务/全部投入资本 (%)2.3922.4872.5183.2152.628
股东权益/带息债务 (%)4,040.5833,885.4573,828.6242,999.3583,682.842
股东权益/负债合计 (%)666.829589.990547.096448.572336.767
利息保障倍数 (X)-10.25143.295-0.162-13.986-89.610

营运能力分析
应收账款周转天数 (天)268.035361.900403.347226.37099.701
存货周转天数 (天)419.093305.642419.425365.800224.891